MedPath

The Cost-effectiveness Analysis of Continuous Intrathecal Morphine Infusion in Cancer Pain Management

Conditions
Cost-effectiveness of continuous intrathecal morphine infusion in cancer pain management.
cost, effectiveness, continuous intrathecal morphine infusion, cancer pain
Registration Number
TCTR20210607005
Lead Sponsor
/A
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending (Not yet recruiting)
Sex
All
Target Recruitment
20
Inclusion Criteria

1.Age over 18 years old
2.Duration of cancer pain more than 3 months
3.Control pain with continuous intrathecal morphine infusion

Exclusion Criteria

1.Patient die within 1 month after receive continuous intrathecal morphine infusion.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Hospital and patient direct cost before and after having ITT price (baht)
Secondary Outcome Measures
NameTimeMethod
analgesic requirement before and after having ITT milligrams morphine equivalent,pain intensity before and after having ITT numeric rating scale (NRS),functional and performance status before and after having ITT palliative performance scale (PPS)
© Copyright 2025. All Rights Reserved by MedPath